We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Monsanto (MON) Set to Gain from Bayer's $66B Buyout Offer
Read MoreHide Full Article
Monsanto Company’s shareowners recently voted to approve the company’s acquisition by the German chemical behemoth,Bayer AG (BAYRY - Free Report) . Under the terms of the merger deal, Monsanto’s shareowners will secure $128 per share in cash at the closing of the deal.
Restoring Hope on Bayer’s Tie-Up
Since the acceptance of Bayer’s buyout offer (Sep 14, 2016), Monsanto’s stock recorded an average negative return of 2.03%, as against 2.57% of negative return provided by the Zacks categorized Agriculture/Products industry.
Sluggish global economy, lower investments in agricultural inputs, volatile weather patterns and sturdy competition in grain exports have been putting pressure on the companies offering services within the global seeds, traits and agricultural chemical industry.
Prominent players within the market such as Syngenta AG (SYT - Free Report) , The Dow Chemical Company (DOW - Free Report) , E. I. du Pont de Nemours and Company (DD - Free Report) and ChemChina; all are heading toward collaboration.
Amid the consolidation contest going on within the industry, Monsanto would likely place itself in a more competitive position by joining hands with the German drug and crop chemical maker.
Moving Ahead
Monsanto declared that Bayer’s partnership would unlock the next tranche of opportunities and growth for its business.
Notably, the stock’s projected sales growth (F1/F0) is currently pegged at 2.41% and estimated earnings per share growth (F1/F0) valued at 4.55%.
In sync with the deal, the company intends to reinforce its existing product portfolio and offer innovative solutions to farmers. Major issues such as food scarcity and rapid climate changes are expected to be addressed more promptly with such services.
Both companies look forward to successfully close the transaction by the fall of 2017. The deal is currently subject to several regulatory approvals and customary closing conditions. However, Bayer has pledged to reimburse a higher break-up fee of $2 billion to Monsanto, in case there is a deal blockage due to regulatory turmoil.
The Best Place to Start Your Stock Search
Today, you are invited to download the full list of 220 Zacks Rank #1 ""Strong Buy"" stocks – absolutely free of charge. Since 1988, Zacks Rank #1 stocks have nearly tripled the market, with average gains of +26% per year. Plus, you can access the list of portfolio-killing Zacks Rank #5 ""Strong Sells"" and other private research. See these stocks free >>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Monsanto (MON) Set to Gain from Bayer's $66B Buyout Offer
Monsanto Company’s shareowners recently voted to approve the company’s acquisition by the German chemical behemoth, Bayer AG (BAYRY - Free Report) . Under the terms of the merger deal, Monsanto’s shareowners will secure $128 per share in cash at the closing of the deal.
Restoring Hope on Bayer’s Tie-Up
Since the acceptance of Bayer’s buyout offer (Sep 14, 2016), Monsanto’s stock recorded an average negative return of 2.03%, as against 2.57% of negative return provided by the Zacks categorized Agriculture/Products industry.
Sluggish global economy, lower investments in agricultural inputs, volatile weather patterns and sturdy competition in grain exports have been putting pressure on the companies offering services within the global seeds, traits and agricultural chemical industry.
Prominent players within the market such as Syngenta AG (SYT - Free Report) , The Dow Chemical Company (DOW - Free Report) , E. I. du Pont de Nemours and Company (DD - Free Report) and ChemChina; all are heading toward collaboration.
Bayer’s $66-billion all-cash buyout price has turned out to be a signature deal for the Zacks Rank #3 (Hold) stock. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Amid the consolidation contest going on within the industry, Monsanto would likely place itself in a more competitive position by joining hands with the German drug and crop chemical maker.
Moving Ahead
Monsanto declared that Bayer’s partnership would unlock the next tranche of opportunities and growth for its business.
Notably, the stock’s projected sales growth (F1/F0) is currently pegged at 2.41% and estimated earnings per share growth (F1/F0) valued at 4.55%.
In sync with the deal, the company intends to reinforce its existing product portfolio and offer innovative solutions to farmers. Major issues such as food scarcity and rapid climate changes are expected to be addressed more promptly with such services.
Both companies look forward to successfully close the transaction by the fall of 2017. The deal is currently subject to several regulatory approvals and customary closing conditions. However, Bayer has pledged to reimburse a higher break-up fee of $2 billion to Monsanto, in case there is a deal blockage due to regulatory turmoil.
The Best Place to Start Your Stock Search
Today, you are invited to download the full list of 220 Zacks Rank #1 ""Strong Buy"" stocks – absolutely free of charge. Since 1988, Zacks Rank #1 stocks have nearly tripled the market, with average gains of +26% per year. Plus, you can access the list of portfolio-killing Zacks Rank #5 ""Strong Sells"" and other private research. See these stocks free >>